“…Follow-up time was available for 99/113 (87.6%) patients [1,2,4-6, 10,14-19,22-24,27,29,30,32,35,36,38,42,45-48,50,53-55,59,61-63,65,66]; mean follow-up was 26 months (range 1-144). In total, 56/99 (56.6%) patients did not relapse [1,2,4,10,13,15,[21][22][23][24][25][26][27][28][29]32,33,36,[39][40][41][42][43]45,47,48,[50][51][52][53][54][55][56][57][58][59]62,65,66], 43/99 (43.4%) of patients relapsed [2,5,6,14,[16][17][18][19]23,…”